Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines

Background: Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype of breast cancer, and current treatments are only partially effective in disease control. More effective combination approaches are needed to improve the survival of TNBC patients. Eribulin mesylate, a non-taxa...

Full description

Bibliographic Details
Main Authors: Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy, Naoto T. Ueno
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Biomedicines
Subjects:
triple-negative breast cancer
eribulin
everolimus
copanlisib
the PI3K/mTOR pathway
Online Access:https://www.mdpi.com/2227-9059/11/3/735

Internet

https://www.mdpi.com/2227-9059/11/3/735

Similar Items